Riskpilot← Back to searchSign inGet full accessNORGESNAPRAPATENE AS
ASActiveOrg 920295223Andre helsetjenester · NACE 86909Est. 20183 employees
Revenue 2022
NOK 2,1M
+21% vs 2021
EBITDA margin
13.9%
+435% vs 2021
Equity ratio
59.1%
Financial strength
Net profit 2022
NOK 188K
+11486% vs 2021
| Revenue | NOK 2,1M | +21% |
| EBITDA | NOK 290K | +435% |
| Net profit | NOK 188K | +11486% |
| Total assets | NOK 515K | +51% |
| Equity | NOK 304K | +162% |
| Employees | 3 | — |
Legal name
NORGESNAPRAPATENE AS
Org number
920295223
Legal form
Aksjeselskap
NACE code
86909 · Andre helsetjenester
Founded
24. januar 2018
Share capital
NOK 3 000 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder hver for seg.
Company purpose
Naprapatklinikk, ergonomirådgivning, treningsveiledning og personlig trening av ulike typer teknikktrening som løping, langrenn, styrke, slyngetrening, funksjonell trening etc. Foredrag innen helse/ernæring/trening/vin. Salg av produkter og tjenester innenfor kostveiledning, og personlig trening, herunder å delta i andre selskap med lignende virksomhet, kjøp og salg av aksjer eller annen måte å gjøre seg interessert i andre foretak.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 1 024 | 1 326 | 1 644 | 1 716 | 2 084 |
| Staff expenses | −623 | −794 | −783 | −924 | −886 |
| EBITDA | 17 | 17 | 133 | 54 | 290 |
| Depreciation & amort. | −4 | −7 | −29 | −23 | −19 |
| EBIT | 13 | 10 | 104 | 31 | 271 |
| Net financials | −0 | 0 | 0 | 0 | −28 |
| Profit before tax | 13 | 10 | 104 | 32 | 242 |
| Tax | 4 | 2 | −0 | 33 | 54 |
| Net profit | 10 | 7 | 104 | −2 | 188 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 242 | 355 | 367 | 342 | 515 |
| Equity | 40 | 47 | 151 | 116 | 304 |
| Long-term debt | 101 | 103 | 103 | 63 | 3 |
| Short-term debt | 102 | 205 | 113 | 163 | 208 |
| Total debt | 202 | 308 | 216 | 226 | 210 |
EBITDA margin
13.9%
This company
15.8%
Market median
-12% vs market
20182022
Equity ratio
59.1%
This company
38.2%
Market median
+55% vs market
20182022
Return on equity
61.8%
This company
18.4%
Market median
+236% vs market
20182022
Net profit margin
9.0%
This company
8.1%
Market median
+11% vs market
20182022
Asset turnover
4.05×
This company
1.12×
Market median
+262% vs market
20182022
Debt / equity
0.69×
This company
0.62×
Market median
+11% vs market
20182022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RK Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORGESNAPRAPATENE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Roy Kjetil Mittet | Chief Executive Officer | 0 companies |
| Yngve Lofthus Teigen | Board of Directors | 0 companies |
| Jannike Mittet | Board of Directors | 0 companies |